NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Vaccination still best protection, but less effective against Delta variant, study finds

Vaccination still best protection, but less effective against Delta variant, study finds

19 August 2021 · Listed under COVID-19, Modernising Medical Microbiology and Big Infection Diagnostics, Translational Data Science

The latest findings of an ongoing national study of COVID-19 immunity in households across the UK has found that the Pfizer-BioNTech and Oxford-AstraZeneca vaccines offer good protection against new infections of the Delta variant of concern, but that effectiveness is reduced compared with the Alpha variant.

The COVID-19 infection survey, led by Oxford University and the Office for National Statistics, found that getting two vaccine doses remains the most effective way to ensure protection against the Delta, the dominant variant in the UK today.

The findings of the latest study – Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK – have been published as a pre-print.

The Chief Investigator on the study is Professor Sarah Walker, the NIHR Oxford BRC’s Co-theme Lead for Antimicrobial Resistance and Modernising Microbiology

The key findings from the study were: 

  • Obtaining two vaccine doses remains the most effective way to ensure protection against the COVID-19 Delta variant of concern
  • With the Delta variant, Pfizer-BioNTech and Oxford-AstraZeneca vaccines still offer good protection against new infections, but effectiveness is reduced compared with Alpha.
  • Two doses of either vaccine still provided at least the same level of protection as having had COVID-19 before through natural infection; people who had been vaccinated after already being infected with COVID-19 had even more protection than vaccinated individuals who had not had COVID-19 before.
  • However, Delta infections after two vaccine doses had similar peak levels of virus to those in unvaccinated people; with the Alpha variant, peak virus levels in those infected post-vaccination were much lower.

Other findings included:

  • A single dose of the Moderna vaccine has similar or greater effectiveness against the Delta variant as single doses of the other vaccines.
  • Two doses of Pfizer-BioNTech have greater initial effectiveness against new COVID-19 infections, but this declines faster compared with two doses of Oxford-AstraZeneca. Results suggest that after four to five months effectiveness of these two vaccines would be similar – however, long-term effects need to be studied.
  • The time between doses does not affect effectiveness in preventing new infections, but younger people have even more protection from vaccination than older people.

Read the full paper.

Find out more about the COVID-19 infection survey

← Second study confirms benefits of budesonide in early stages of COVID-19
New study launched to understand vaccine escape →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre